Annual General Meeting of Lonza Group Ltd

March 31,2010 Basel, Switzerland

Today’s Annual General Meeting of Lonza Group Ltd led by the Chairman of the Board of Directors, Rolf Soiron, was attended by 389 shareholders. They represented 38,26% of the sharecapital.

The Shareholders supported all motions proposed by the Board of Directors.

A dividend of CHF 1.75 per share will be paid out on 12 April 2010.

The Board members standing for re-election (Dame Julia Higgins, Gerhard Mayr, Rolf Soiron, Sir Richard Sykes, Patrick Aebischer and Peter Wilden) were all elected for a further term in office of one year.

About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2009, Lonza had sales of CHF 2.690 billion. Further information can be found at

For further Information

Lonza Group Ltd
Head Corporate Communications
Michael Frizberg
Tel +41 61 316 8624
Fax +41 61 316 9624

Lonza Group Ltd
Media Relations
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798

Lonza Group Ltd
Investor Relations
Dirk Oehlers
Tel +41 61 316 8540
Fax +41 61 316 9540

Browse All News